Track the Hill-Rom Holdings, Inc. stock price and the full directors' dealings record of the company, a listed issuer based in United States. Shares are quoted on US US, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, Hill-Rom Holdings, Inc. has recorded 82 insider filings. The latest transaction was filed on 15 December 2021 (Disposition). Among the most active insiders: Ladone Mary Kay. The full history is accessible without an account.
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
25 of 82 declarations
Hill-Rom Holdings, Inc. was a U.S.-based medical technology company listed on the NYSE under the ticker HRC. It was incorporated in 1969 in Indiana and was headquartered in Chicago, Illinois, United States. Historically, Hill-Rom built its reputation as a provider of hospital equipment and connected care solutions, serving acute-care hospitals, post-acute settings, and home-care environments. Its brand was particularly associated with hospital beds, therapeutic support surfaces, fall and pressure-injury prevention systems, continuous patient monitoring, respiratory care devices, and related clinical workflow solutions. ([sec.gov](https://www.sec.gov/Archives/edgar/data/47518/000004751817000130/a2017q410k.htm?utm_source=openai)) From a business-model perspective, Hill-Rom operated across complementary product and service lines centered on patient support, front-line care, and respiratory/home-care therapies. That mix gave the company exposure to both capital equipment and recurring clinical needs. Its competitive position was supported by an established installed base, long-standing customer relationships with healthcare providers, and a strong focus on technologies designed to improve patient safety, detect deterioration earlier, and reduce avoidable complications in clinical settings. ([hillrom.com](https://www.hillrom.com/en/products/centrella-smart-bed/?utm_source=openai)) Geographically, Hill-Rom had a meaningful U.S. footprint and also operated internationally. In its 2020 SEC filing, the company reported approximately 10,000 employees worldwide, with about 6,000 in the United States and about 4,000 outside the United States, underscoring that it was a domestically anchored company with global reach. ([sec.gov](https://www.sec.gov/Archives/edgar/data/47518/000004751820000129/hrc-20200930.htm?utm_source=openai)) The most important recent development was Baxter International’s acquisition of Hillrom. Baxter announced the transaction in September 2021 and completed it on December 13, 2021. Baxter described the deal as a way to expand connected-care capabilities, broaden access across the hospital, home, and alternate-site continuum, and accelerate innovation and international expansion. As a result, Hill-Rom ceased to exist as an independent publicly traded company, so historical SEC filings—including insider Form 4 transactions—should be interpreted in that context. For investors, this means Hill-Rom is best viewed as a legacy medtech franchise now embedded in Baxter rather than an active standalone listed issuer. ([baxter.com](https://www.baxter.com/baxter-newsroom/baxter-acquire-hillrom-expanding-connected-care-and-medical-innovation-globally?utm_source=openai))